A third shot of Sinopharm’s Covid-19 vaccine leads to a rebound in antibody levels that drop months after a second dose, a small-scale Chinese study showed.
Several Asian nations are quickly ramping up vaccination campaigns from shaky starts to combat growing Covid-19 infections, as supply shipments roll in and people overcome hesitancy in hopes of easing curbs and freeing up travel.
The controversy surrounding Covid-19’s origin continues to heat up, as the National Institutes of Health’s recent removal of genetic data about the novel coronavirus virus from the NIH archive was brought into the spotlight.
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. Food and Drug Administration, which will speed up the regulatory process for these medications.
A U.S. appeals court on Aug. 10 threw out a price-fixing lawsuit against two Chinese companies that make vitamin C, a case that spotlighted trade tensions between the United States and China.
Seagen (formerly known as Seattle Genetics) forged an exclusive licensing agreement with China’s RemeGen to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC).
Antibody levels in people inoculated with CanSino Biologics’ (CanSinoBIO) single-dose Covid-19 vaccine fell by some 30 percent after six months, however a booster shot could offer a significant lift, a senior executive said on Aug. 5.
The U.S. Securities and Exchange Commission halted registrations of U.S. initial public offerings (IPOs) by Chinese companies.
Three pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.
Antibodies triggered by Sinovac Biotech’s Covid-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.